The CAR T-Cell Therapy Clinical Journey Guide



Immune Effector Cell-Associated Neurotoxicity Syndrome


Informed Consent Form

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS, or neurotoxicity)

A severe side effect of CAR T-cell therapy in which the immune response can produce a toxic effect on the nervous system. Patients may suffer headaches, confusion, seizures, loss of speech and loss of motor skills. ICANS can range from very mild to quite severe and life-threatening.


A type of treatment that uses the immune system to treat disease (including cancer).

Inclusion criteria

Factors that a patient must have in order to participate in a particular clinical trial.

Informed consent

See Participant Information Sheet.

Informed consent process

A process that makes sure clinical trial participants are fully informed about and understand all the details of a clinical trial before agreeing to participate.

Intravenous immunoglobulin (IVIG)

A treatment often given to people who have received CAR T-cell therapy. IVIG provides extra antibodies and helps to prevent frequent infections until B cells return to more normal levels.


A person responsible for the conduct of a clinical trial at the clinical research site. If there is more than one investigator at a site, the leader is called the “Principal Investigator”.


Intravenous Immunoglobulin